Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Medullary thyroid carcinoma: the influence of policy changing in clinical characteristics and disease progression.

Alevizaki M, Saltiki K, Rentziou G, Papathoma A, Sarika L, Vasileiou V, Anastasiou E.

Eur J Endocrinol. 2012 Dec;167(6):799-808. doi: 10.1530/EJE-12-0388. Epub 2012 Sep 18.

2.

Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients.

Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC, Rubello D.

Eur J Surg Oncol. 2007 May;33(4):493-7. Epub 2006 Nov 27.

PMID:
17125960
3.

Long-term prognosis of medullary thyroid carcinoma.

Rendl G, Manzl M, Hitzl W, Sungler P, Pirich C.

Clin Endocrinol (Oxf). 2008 Sep;69(3):497-505. doi: 10.1111/j.1365-2265.2008.03229.x. Epub 2008 Mar 10.

PMID:
18331612
4.

Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.

Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH.

Cancer. 2000 Mar 1;88(5):1139-48.

PMID:
10699905
5.

Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients.

Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB.

Surgery. 2003 Dec;134(6):890-9; discussion 899-901.

PMID:
14668720
6.

Clinical and oncological features of children and young adults with multiple endocrine neoplasia type 2A.

Puñales MK, da Rocha AP, Meotti C, Gross JL, Maia AL.

Thyroid. 2008 Dec;18(12):1261-8. doi: 10.1089/thy.2007.0414.

PMID:
18991485
7.

Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course.

Leboulleux S, Travagli JP, Caillou B, Laplanche A, Bidart JM, Schlumberger M, Baudin E.

Cancer. 2002 Jan 1;94(1):44-50.

8.

Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.

Karga H, Giagourta I, Papaioannou G, Doumouchtsis K, Polymeris A, Thanou S, Papamichael K, Zerva C.

Metabolism. 2011 May;60(5):604-8. doi: 10.1016/j.metabol.2010.06.004. Epub 2010 Jul 29.

PMID:
20667564
9.

Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma.

Franc S, Niccoli-Sire P, Cohen R, Bardet S, Maes B, Murat A, Krivitzky A, Modigliani E; French Medullary Study Group (GETC).

Clin Endocrinol (Oxf). 2001 Sep;55(3):403-9.

PMID:
11589685
10.

Prognostic variables and calcitonin in medullary thyroid cancer.

Clark JR, Fridman TR, Odell MJ, Brierley J, Walfish PG, Freeman JL.

Laryngoscope. 2005 Aug;115(8):1445-50.

PMID:
16094121
11.

Simultaneous medullary and differentiated thyroid cancer: a population-level analysis of an increasingly common entity.

Wong RL, Kazaure HS, Roman SA, Sosa JA.

Ann Surg Oncol. 2012 Aug;19(8):2635-42. doi: 10.1245/s10434-012-2357-8. Epub 2012 Apr 17.

PMID:
22526904
12.

Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression.

Saltiki K, Rentziou G, Stamatelopoulos K, Georgiopoulos G, Stavrianos C, Lambrinoudaki E, Alevizaki M.

Eur J Endocrinol. 2014 Jul;171(1):117-26. doi: 10.1530/EJE-14-0076. Epub 2014 Apr 23.

13.

Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin.

Mirallié E, Iacobone M, Sebag F, Henry JF.

Eur J Surg Oncol. 2004 Sep;30(7):790-5.

PMID:
15296996
14.

Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients.

Kaserer K, Scheuba C, Neuhold N, Weinhäusel A, Haas OA, Vierhapper H, Niederle B.

Am J Surg Pathol. 2001 Oct;25(10):1245-51.

PMID:
11688458
15.

Surgical management of sporadic medullary thyroid cancer.

Noullet S, Trésallet C, Godiris-Petit G, Hoang C, Leenhardt L, Menegaux F.

J Visc Surg. 2011 Sep;148(4):e244-9. doi: 10.1016/j.jviscsurg.2011.07.009. Epub 2011 Aug 31. Review.

PMID:
21885365
16.

Medullary thyroid microcarcinoma: a clinicopathologic retrospective study of 38 patients with no prior familial disease.

Guyétant S, Dupre F, Bigorgne JC, Franc B, Dutrieux-Berger N, Lecomte-Houcke M, Patey M, Caillou B, Viennet G, Guerin O, Saint-Andre JP.

Hum Pathol. 1999 Aug;30(8):957-63.

PMID:
10452509
17.

Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules.

Rieu M, Lame MC, Richard A, Lissak B, Sambort B, Vuong-Ngoc P, Berrod JL, Fombeur JP.

Clin Endocrinol (Oxf). 1995 May;42(5):453-60.

PMID:
7621562
18.

Latent subclinical medullary thyroid carcinoma: diagnosis and treatment.

Henry JF, Denizot A, Puccini M, Gramatica L, Kvachenyuk A, Conte Devolx B, De Micco C.

World J Surg. 1998 Jul;22(7):752-6; discussion 756-7.

PMID:
9606293
19.

[Surgical treatment and prognosis analysis on medullary thyroid carcinoma].

Zhang ZX, Li ZJ, Tang PZ, Xu ZG, Zhang ZM, An CM.

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Mar;46(3):209-13. Chinese.

PMID:
21575412
20.

[Early therapeutic management of patients genetically predisposed to medullary thyroid cancer].

Murat A, Modigliani E, Conte-Devolx B, Rohmer V, Leclerc L, Guilhem I, Bigorgne JC, Boneu A, Maes B, Chabre O, Niccoli P, Schuffenecker I, Giraud S.

Ann Chir. 1998;52(5):455-60. French.

PMID:
9752487
Items per page

Supplemental Content

Write to the Help Desk